Cytotoxic properties of sunitinib and sorafenib on human corneal epithelial cells

Current Eye Research

Volumn 39, Issue 2, 2014, Pages 149-154

  Bayyoud, Tarek ^a   Hofmann, Johanna ^a   Spitzer, Martin ^a   Bartz Schmidt, Karl Ulrich ^a   Yoeruek, Efdal ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Corneal vascularization; Human corneal epithelial cells; Platelet derived growth factor; Sorafenib; Sunitinib; Vascular endothelial growth factor

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN P63; SORAFENIB; SUNITINIB; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; CKAP4 PROTEIN, HUMAN; INDOLE DERIVATIVE; MEMBRANE PROTEIN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TUMOR PROTEIN;

ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA NEOVASCULARIZATION; DONOR; DRUG CYTOTOXICITY; EYE TOXICITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MONOLAYER CULTURE; MTT ASSAY; PHASE CONTRAST MICROSCOPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PHASE CONTRAST MICROSCOPY; TOXICITY;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; CELL LINE; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM, CORNEAL; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; MICROSCOPY, PHASE-CONTRAST; NEOPLASM PROTEINS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84893022467     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2013.833629     Document Type: Article

References (24)

1. Azar DT. Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006;104: 264-302.
2. Pérez-Santonja JJ, Campos-Mollo E, Lledo-Riquelme M, Javaloy J, Alio JL. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti- VEGF and Anti-PDGF) in an animal model. Am J Ophthalmol 2010;150:519-528.
3. Amano S, Rohan A, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22.
4. Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: Histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1998;17: 611-613.
5. Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 2000;19:526-533.
6. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization. Pathogenesis and inhibition. Cornea 1987;6:250-257.
7. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82:557-563.
8. Dana MR, Schaumberg DA, Kowal VO, Goren MB, Rapuano CJ, Laibson PR, et al. Corneal neovascularization after penetrating keratoplasty. Cornea 1995;14:604-609.
9. Hill JC, Maske R. An animal model for corneal graft rejection in high-risk keratoplasty. Transplantation 1988;46: 26-30.
10. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-1157.
11. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36: 331-335.
12. Dell S, Peters S, Muther P, Kociok N, Joussen AM. The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. Invest Ophthalmol Vis Sci 2006;47:1928-1937.
13. Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of antivascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168: 2036-2053.
14. Kim TI, Kim SW, Kim S, Kim T, Kim EK. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008; 27:349-352.
15. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804-807.
16. Kvanta A. Ocular angiogenesis: The role of growth factors. Acta Ophthalmol Scand 2006;84:282-288.
17. Roskoski Jr R. Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007;356:323-328.
18. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz- Schmidt KU. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158-160.
19. Chow LQ, Eckhardt SG. Sunitinib: From rational design to clinical efficacy. J Clin Oncol 2007;25:884-896.
20. Pankaj Bhargava, Murray O. Robinson. Development of second-generation VEGFR tyrosine kinase inhibitors: Current status. Curr Oncol Rep 2011;13:103-111.
21. de Paiva CS, Chen Z, Corrales RM, Pflugfelder SC, Li DQ. ABCG2 transporter identifies a population of clonogenic human limbal epithelial cells. Stem Cells 2005; 23:63-73.
22. Reidy JJ, Hershberger DH, Campbell LM, Seigel GM. p63 and ABCG2 expression in the corneoscleral limbus: Implications for stem cell purification. Invest Ophthalmol Vis Sci 2004;45:E-Abstract 3393.
23. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz- Schmidt KU. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26:977-982.
24. Seo JW, Chung SH, Choi JS, Joo CK. Inhibition of corneal neovascularization in rats by systemic administration of sorafenib. Cornea 2012;31:907-912.